drugset / Trial / NCT05193565

Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients

NCT05193565

Phase 4 Active not recruiting 206 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and Safety after conversion to RaparoBell® or Myrept® in patients who in renal transplant patients undergoing maintenance therapy with Mycophenolic acid.

Timeline

Start
2021-11-19
Primary completion
2026-07
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mycophenolate Mofetil Small molecule 1 g
Subject Sirolimus Small molecule Oral

Indications

No indication recorded.